US FDA ORDERS NEW EYE RISK WARNINGS FOR OZEMPIC AND ZEPBOUND

The US FDA ‌on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.

The US Food and Drug Administration said it is requiring GLP-1 drugs such ​as Eli Lilly's Mounjaro and Zepbound, and Novo Nordisk's Ozempic and Wegovy to add information ​to the "warnings and precautions" section of labeling about the potential increased risk of non-arteritic ⁠anterior ischemic optic neuropathy (NAION).

Learn More